Genmab — Februar 2026

[mortendrost1]

Ja, jeg har også lige købt, efter den nu er banket i bund. Vil gerne lige over 1836 og gerne 1850 i dag. Så kan det være en klassisk rysten med træet.

[StockBull]

Under 1.750 bliver det mere bearish, men det kræver typisk en ny trigger (f.eks. macro-salg i biotech eller negativ nyhed).

[StockBull]

Jeg køber dip nær 1.835–1.750 - alternativt kan man vente på bekræftelse (f.eks. close over 1.850–1.870)?

[mortendrost1]

Ja, enig i at 1850 vil stoppe det

[mortendrost1]

1850 vil stoppe faldet skulle der stå

[StockBull]

Ja enig

[concillado]

Det lader til at Danske Bank begynder at tilbagekøbe for GEN nu ;-).... kurs 1850

[mortendrost1]

Såh luner det lidt igen. lad os se om den modreaktion vare ved

[concillado]

Yup, tilbagekøb i et lidt surt marked er lidt som at tisse i bukserne

[gentogen]

A Study of GEN1106 in Participants With Solid Tumors.This is a first-in-human (FIH), open-label, multicenter, dose escalation and expansion trial in participants with urothelial and other cancers who have metastatic disease.https://clinicaltrials.gov/study/NCT07416123?term=genmab&aggFilters=status:not&rank=2

[E_L]

William Blair analyst Matt Phipps has reiterated their bullish stance on GMAB stock, giving a Buy rating today. https://www.tipranks.com/news/ratings/genmab-near-term-guidance-miss-offset-by-strong-results-and-blockbuster-late-stage-pipeline-upside-ratings-news

[E_L]

Goldman Sachs has lowered its price target for Genmab to 1,771 Danish kroner (previously 1,793), while reiterating its neutral rating

[ProinvestorNEWS]

Genmab/AL Sydbank: Investorerne fælder hård dom - fokus bør være på pipelinen https://proinvestor.com/investornyt/1413609/genmab-al-sydbank-investorerne-faelder-hard-dom-fokus-bor-vaere-pa-pipelinen

[E_L]

H.C. Wainwright raised the firm's price target on Genmab to $40 from $39 and keeps a Buy rating

[E_L]

if i would have to guess, i would say that is the ADC @gentogen , GEN1107
was a Profound Bio ADC ?

[gentogen]

sounds reasonable

[E_L]

Genmab fik 79 mio. kr. i betaling fra Novo Nordisk i 2025
Genmab fik samlet set 97 mio. dollar – svarende til over 613 mio. kr. – i milepælsbetalinger fra selskabets partnere i 2025. https://medwatch.dk/brancher/Medicinal___Biotek/article19028155.ece

[gentogen]

Ja, Og godt 4,1 milliarder kroner i royalties fra andet end dara

[E_L]

Charlie Haywood from Bank of America Securities maintained a Buy rating on Genmab A/S, with a price target of DKK2,500

[E_L]

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-breakthrough-therapy-designation-for-patients-with-advanced-head-and-neck-cancer